| 7449462 |
Triazole derivatives which inhibit vasopressin antagonistic activity |
Justin Stephen Bryans, Patrick Stephen Johnson, Thomas Ryckmans |
2008-11-11 |
$189,542,000 |
| 7442795 |
Triazole compounds useful in therapy |
Justin Stephen Bryans, Patrick Stephen Johnson, Thomas Ryckmans |
2008-10-28 |
$154,383,000 |
| 7378436 |
Compounds |
Paul Vincent Fish, Michael J. Fray, Florian Wakenhut, Gavin Alistair Whitlock, Mark Andrews +2 more |
2008-05-27 |
$99,152,000 |
| 7129234 |
Phenyl heterocyclyl ethers |
Mavis Adam, Mark Andrews, Geoffrey E. Gymer, David Hepworth, Harry Howard +1 more |
2006-10-31 |
$291,859,000 |
| 7122683 |
Amides useful as monoamine re-uptake inhibitors |
Paul Vincent Fish, Thomas Ryckmans, Florian Wakenhut, Gavin Alistair Whitlock |
2006-10-17 |
$200,439,000 |
| 7119088 |
Triazole compounds useful in therapy |
Justin Stephen Bryans, Patrick Stephen Johnson, Thomas Ryckmans |
2006-10-10 |
$197,936,000 |
| 7060836 |
Lactams as tachykinin antagonists |
Donald Middleton |
2006-06-13 |
$276,459,000 |
| 6979690 |
Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators |
Geoffrey E. Gymer, Kiyoshi Kawamura, Sachiko Mihara, Mikio Morita, Chikara Uchida +1 more |
2005-12-27 |
$223,783,000 |
| 6936619 |
Quinazolinone compounds useful in therapy |
Julian Blagg, Michael J. Fray, Mark Llewellyn Lewis, John Paul Mathias, Mark Henryk Stefaniak |
2005-08-30 |
$247,137,000 |
| 6849649 |
N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
Stephen Challenger, Andrew Cook, Adam Gillmore, Donald Middleton, David Cameron Pryde |
2005-02-01 |
$221,993,000 |
| 6660756 |
N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
Stephen Challenger, Andrew Cook, Adam Gillmore, Donald Middleton, David Cameron Pryde |
2003-12-09 |
$301,764,000 |
| 6630504 |
Phenoxyphenylheterocyclyl derivatives as SSRIs |
Mark Andrews, David Hepworth, Donald Middleton |
2003-10-07 |
$307,545,000 |
| 6624162 |
Imidazopyridine compounds as 5-HT4 receptor modulators |
Chikara Uchida, Hirohide Noguchi, Geoffrey E. Gymer, David Fenwick |
2003-09-23 |
$636,328,000 |
| 6610747 |
Phenoxybenzylamine derivatives as SSRIs |
Mavis Adam, Mark Andrews, Mark Elliott, Geoffrey E. Gymer, David Hepworth +2 more |
2003-08-26 |
$177,412,000 |
| 6448293 |
Diphenyl ether compounds useful in therapy |
Mark Andrews, David Hepworth, Donald Middleton |
2002-09-10 |
$252,411,000 |
| 6376490 |
Quinoxalinediones |
David John Bull, Christopher Lee Carr, Michael J. Fray, Elisabeth Colette Louise Gautier, Charles Eric Mowbray |
2002-04-23 |
$303,971,000 |
| 6333326 |
Quinoxalinediones |
Elisabeth Colette Louise Gautier, David Waite, Robert James Crook |
2001-12-25 |
|
| 5863917 |
Quinoxaline derivatives useful in therapy |
Charles Eric Mowbray |
1999-01-26 |
$624,841,000 |
| 5852016 |
Quinoxaline derivatives useful in therapy |
Michael J. Fray, Charles Eric Mowbray |
1998-12-22 |
$228,111,000 |
| 5783572 |
Quinoxalinedione NMDA receptor antagonists |
Charles Eric Mowbray, Michael J. Fray, David John Bull, Christopher Lee Carr |
1998-07-21 |
$257,547,000 |
| 5543419 |
Quinuclidine esters process and intermediate for their preparation and pharmaceutical compositions containing them |
Peter E. Cross |
1996-08-06 |
$66,263,000 |
| 5292749 |
Antimuscarinic bronchodilators |
— |
1994-03-08 |
$58,896,000 |
| 5171744 |
Antimuscarinic bronchodilators |
Peter E. Cross |
1992-12-15 |
$46,231,000 |
| 4806557 |
Dihydropyridines and use thereof in treating hypertension and ischaemia |
Simon F. Campbell, Michael Humphrey |
1989-02-21 |
$13,418,000 |
